犬细小病毒特异性免疫球蛋白的临床应用效果观察

旨在观察犬细小病毒特异性免疫球蛋白治疗犬细小病毒病的临床应用效果，本文收集了中国农业大学动物医院自2016年1月—2019年11月接治的犬细小病毒病患犬的病历资料，筛选出病历资料完整的并使用了犬细小病毒单抗或犬细小病毒特异性免疫球蛋白治疗的患犬病例进行跟踪以及回访。对收集的病例数据进行了总治愈率、各初始抗体水平的治愈率、各月龄段的治愈率和治愈病例的病程分析。结果显示，犬细小病毒特异性免疫球蛋白和犬细小病毒单克隆抗体在总治愈率、相同初始抗体水平治愈率、相同月龄段治愈率均无显著差异（P>0.05）。但使用特异性免疫球蛋白的病例痊愈时间显著低于使用单克隆抗体的病例（P=0.02<0.05）。综上表明，犬细小病毒特异性免疫球蛋白的临床应用效果良好，可为犬细小病毒病的治疗提供新的药物选择。

Observation on the Clinical Application Effect of Canine Parvovirus Specific Immunoglobulin

In order to explore the clinical application effect of canine parvovirus (CPV) specific immunoglobulin in the treatment of CPV disease, we collected the case records of CPV infected dogs received and treated in Animal Hospital of China Agricultural University from January 2016 to November 2019, and screened out the dogs with complete medical records and were treated with CPV monoclonal antibody or CPV specific immunoglobulin. These dogs were tracked return visit. We analyzed the total cure rate, the cure rate of each initial antibody levels and each month ages and the recovery course of those cases. The results showed that there was no significant difference between CPV specific immunoglobulin and CPV monoclonal antibody in the total cure rate and the cure rate of consistent initial antibody levels and consistent month ages (P>0.05). However, the recovery course of dogs treated with specific immunoglobulin was significantly lower than those treated with monoclonal antibody (P=0.02<0.05). The good clinical application effect of canine parvovirus specific immunoglobulin provides a new choice of drugs treating CPV disease.